Jubilant Share Price Increases Following FDA Approval

News: According to Business Standard, India-based pharmaceutical firm Jubilant Organosys has registered a 13% increase in share prices on the Bombay Stock Exchange (BSE) on May 5 2009. This is mainly due to the approval of its generic drug Sestamibi by the US FDA. The drug is manufactured by its US-based subsidiary Draximage and is estimated to have a market share of US$400mn.

To read the full article, please choose one of the following options: